FDA pharmacologic class
Programmed Death Receptor-1 Blocking Antibody
7 medicines are in FDA's class of programmed death receptor-1 blocking antibodies: nivolumab (Opdivo), tislelizumab (Tevimbra), atezolizumab (Tecentriq), dostarlimab (Jemperli), pembrolizumab (Keytruda), retifanlimab (Zynyz) and toripalimab (Loqtorzi); 4 combination products also contain one. 0 of the 11 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are programmed death receptor-1 blocking antibody?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Nivolumab | Opdivo | none listed | n/a | No | No current entry | 1 |
| Tislelizumab | Tevimbra | none listed | n/a | No | No current entry | 0 |
| Atezolizumab | Tecentriq | none listed | n/a | No | No current entry | 1 |
| Berahyaluronidase alfa and pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 0 |
| Hyaluronidase and nivolumab | Opdivo | none listed | n/a | No | No current entry | 0 |
| Atezolizumab and hyaluronidase | Tecentriq | none listed | n/a | No | No current entry | 0 |
| Dostarlimab | Jemperli | none listed | n/a | No | No current entry | 0 |
| Nivolumab and relatlimab | Opdualag | none listed | n/a | No | No current entry | 1 |
| Pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 1 |
| Retifanlimab | Zynyz | none listed | n/a | No | No current entry | 0 |
| Toripalimab | Loqtorzi | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)